Comparative Pharmacology
Head-to-head clinical analysis: DOXYCYCLINE versus MECLAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYCYCLINE versus MECLAN.
DOXYCYCLINE vs MECLAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex. It also exhibits anti-inflammatory and anti-collagenase activities.
Meclizine is an antihistamine with central anticholinergic properties. It blocks histamine H1 receptors and exerts antiemetic effects via inhibition of the vestibular system and chemoreceptor trigger zone.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg every 12 hours or 50 mg every 6 hours.
250 mg orally three times daily for 7-14 days; for sinusitis: 500 mg three times daily.
None Documented
None Documented
Clinical Note
moderateMethoxsalen + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Methoxsalen."
Clinical Note
moderateCyclophosphamide + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Cyclophosphamide."
Clinical Note
moderatePaclitaxel + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Paclitaxel."
Clinical Note
moderateDocetaxel + Doxycycline
Terminal elimination half-life is 18–24 hours in patients with normal renal function; prolonged to 20–30 hours in renal impairment; allows once or twice daily dosing.
Terminal elimination half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Renal (40%) and fecal/biliary (60%); undergoes enterohepatic circulation; active drug and metabolites excreted in urine and feces.
Renal excretion of unchanged drug and metabolites: ~70%; fecal/biliary: ~30%.
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic
"The metabolism of Doxycycline can be decreased when combined with Docetaxel."